Pseudomonas aeruginosa and reserve drugs
Pseudomonas aeruginosa i rezervni lekovi
Апстракт
This investigation tested 312 strains of pseudomonas aeruginosa. Out of them 70% were urine isolates, and 30% were taken from different pathogenic materials. Sensitivity of P. aeruginosa was tested to: penicillin, amikacin ceftazidime, ciprofloxacin, ofloxacin and fleroxacin. In order to test sensitivity of P. aeruginosa to reserve drugs, agar-dilution method was used, and its sensitivity was expressed with minimal inhibitory concentration (MIC). On the basis of our results 93.6% of strains were susceptible to piperacillin, and only 6.4% were resistant, with MIC50 6,3 μg/ml. High susceptibility was also established to ceftazidime (82%, with 10.6% resistant strains and MIC50 3,1 μg/ml) so this drug can also be used as a drug of choice in for P. aeruginosa. Good susceptibility was established to amikacin (60.2%, and 33.6% resistant strains with MIC50 12,5 μg/ml). Moderate susceptibility was established to ciprofloxacin (45.8% susceptible strains and 49.3% resistant strains with MIC50 1,5...6 μg/ml). Poor susceptibility was established to ofloxacin and fleroxacin with 57.4% resistant strains to ofloxacin and 59% to fleroxacin; moderate susceptibility to ofloxacin was established for 25.6% of strains and to fleroxacin for 30.4%; only 17% of strains were ofloxacin susceptible and 10.6% fleroxacin susceptible, with MIC50 6,3 μg/ml, discrediting both drugs as antipseudomonas drugs.
U radu je testirano 312 sojeva Ps. aeruginosa. Od toga 70 % izolata potiče iz urina, a preostalih 30% potiče iz različitog patološkog materijala. Osetljivost Ps. aeruginosa ispitivana je prema: Piperacilinu, Amikacinu Ceftazidimu, Ciprofloksacinu, Ofloksacinu i Fleroksacinu. Za ispitivanje osetljivosti Ps. aeruginosa na rezervne lekove, korišćen je agar-dilucioni metod, pri čemu je osetljivost ove bakterije izražena minimalnom inhibitornom koncentracijom (MIC). Na osnovu našeg rada vodeći među testiranim antibioticima je antipseudomonasni lek Piperacilin sa 93,6% piperacilin osetljivih sojeva i svega 6,4% piperacilin rezistentnih sojeva i MIC50 6,3mg/ml. Visoku osetljivost ispitivani sojevi Ps. aeruginosa pokazali su prema Ceftazidimu sa 82% Ceftazidim osetljivih i svega 10,6% Ceftazidim rezistentnih sojeva i MIC50 3,1mg/ml, te se i on može koristiti kao lek izbora za Ps. aeruginosa. Dobru osetljivost pokazali su ispitivani sojevi prema Amikacinu 60,2% je Amikacin osetljivih sojeva i 3...3,6% Amikacin rezistentnih sojeva sa MIC50 12,5mg/ml. Umerenu osetljivost pokazali su ispitivani sojevi prema Ciprofloksacinu sa 45,8% osetljivih i 49,3% rezistentnih sojeva i MIC50 1,56mg/ml. Slabu osetljivost pokazali su ispitivani sojevi prema Ofloksacinu i Fleroksacinu, pri čemu je Ofloksacin rezistentnih sojeva 57,4%, odnosno Fleroksacin rezistentnih 59%; umereno Ofloksacin osetljivih 25,6%, odnosno umereno Fleroksacin osetljivih 30,4% i svega Ofloksacin osetljivih 17%, odnosno Fleroksacin osetljivih 10,6% a MIC50 Ofloksacina i Fleroksacina je 6,3mg/ml, što ova dva leka i diskredituje iz grupe antipseudomonasnih lekova.
Кључне речи:
Pseudomonas Aeruginosa / drug therapy / Antibiotics / Drug Therapy / Piperacillin / Pseudomonas aeruginosa / antibiotici / Ofloksacin / FleroksacinИзвор:
Medicina danas, 2004, 3, 1-2, 176-180Издавач:
- Nestranačko, nevladino i neprofitno udruženje građana Medicina danas - pokret evropskih inicijativa, Novi Sad
Институција/група
TorlakTY - JOUR AU - Aleksić-Živić, Jasminka AU - Mraović, Mirjana AU - Živić, Milan PY - 2004 UR - http://intor.torlakinstitut.com/handle/123456789/186 AB - This investigation tested 312 strains of pseudomonas aeruginosa. Out of them 70% were urine isolates, and 30% were taken from different pathogenic materials. Sensitivity of P. aeruginosa was tested to: penicillin, amikacin ceftazidime, ciprofloxacin, ofloxacin and fleroxacin. In order to test sensitivity of P. aeruginosa to reserve drugs, agar-dilution method was used, and its sensitivity was expressed with minimal inhibitory concentration (MIC). On the basis of our results 93.6% of strains were susceptible to piperacillin, and only 6.4% were resistant, with MIC50 6,3 μg/ml. High susceptibility was also established to ceftazidime (82%, with 10.6% resistant strains and MIC50 3,1 μg/ml) so this drug can also be used as a drug of choice in for P. aeruginosa. Good susceptibility was established to amikacin (60.2%, and 33.6% resistant strains with MIC50 12,5 μg/ml). Moderate susceptibility was established to ciprofloxacin (45.8% susceptible strains and 49.3% resistant strains with MIC50 1,56 μg/ml). Poor susceptibility was established to ofloxacin and fleroxacin with 57.4% resistant strains to ofloxacin and 59% to fleroxacin; moderate susceptibility to ofloxacin was established for 25.6% of strains and to fleroxacin for 30.4%; only 17% of strains were ofloxacin susceptible and 10.6% fleroxacin susceptible, with MIC50 6,3 μg/ml, discrediting both drugs as antipseudomonas drugs. AB - U radu je testirano 312 sojeva Ps. aeruginosa. Od toga 70 % izolata potiče iz urina, a preostalih 30% potiče iz različitog patološkog materijala. Osetljivost Ps. aeruginosa ispitivana je prema: Piperacilinu, Amikacinu Ceftazidimu, Ciprofloksacinu, Ofloksacinu i Fleroksacinu. Za ispitivanje osetljivosti Ps. aeruginosa na rezervne lekove, korišćen je agar-dilucioni metod, pri čemu je osetljivost ove bakterije izražena minimalnom inhibitornom koncentracijom (MIC). Na osnovu našeg rada vodeći među testiranim antibioticima je antipseudomonasni lek Piperacilin sa 93,6% piperacilin osetljivih sojeva i svega 6,4% piperacilin rezistentnih sojeva i MIC50 6,3mg/ml. Visoku osetljivost ispitivani sojevi Ps. aeruginosa pokazali su prema Ceftazidimu sa 82% Ceftazidim osetljivih i svega 10,6% Ceftazidim rezistentnih sojeva i MIC50 3,1mg/ml, te se i on može koristiti kao lek izbora za Ps. aeruginosa. Dobru osetljivost pokazali su ispitivani sojevi prema Amikacinu 60,2% je Amikacin osetljivih sojeva i 33,6% Amikacin rezistentnih sojeva sa MIC50 12,5mg/ml. Umerenu osetljivost pokazali su ispitivani sojevi prema Ciprofloksacinu sa 45,8% osetljivih i 49,3% rezistentnih sojeva i MIC50 1,56mg/ml. Slabu osetljivost pokazali su ispitivani sojevi prema Ofloksacinu i Fleroksacinu, pri čemu je Ofloksacin rezistentnih sojeva 57,4%, odnosno Fleroksacin rezistentnih 59%; umereno Ofloksacin osetljivih 25,6%, odnosno umereno Fleroksacin osetljivih 30,4% i svega Ofloksacin osetljivih 17%, odnosno Fleroksacin osetljivih 10,6% a MIC50 Ofloksacina i Fleroksacina je 6,3mg/ml, što ova dva leka i diskredituje iz grupe antipseudomonasnih lekova. PB - Nestranačko, nevladino i neprofitno udruženje građana Medicina danas - pokret evropskih inicijativa, Novi Sad T2 - Medicina danas T1 - Pseudomonas aeruginosa and reserve drugs T1 - Pseudomonas aeruginosa i rezervni lekovi EP - 180 IS - 1-2 SP - 176 VL - 3 UR - https://hdl.handle.net/21.15107/rcub_intor_186 ER -
@article{ author = "Aleksić-Živić, Jasminka and Mraović, Mirjana and Živić, Milan", year = "2004", abstract = "This investigation tested 312 strains of pseudomonas aeruginosa. Out of them 70% were urine isolates, and 30% were taken from different pathogenic materials. Sensitivity of P. aeruginosa was tested to: penicillin, amikacin ceftazidime, ciprofloxacin, ofloxacin and fleroxacin. In order to test sensitivity of P. aeruginosa to reserve drugs, agar-dilution method was used, and its sensitivity was expressed with minimal inhibitory concentration (MIC). On the basis of our results 93.6% of strains were susceptible to piperacillin, and only 6.4% were resistant, with MIC50 6,3 μg/ml. High susceptibility was also established to ceftazidime (82%, with 10.6% resistant strains and MIC50 3,1 μg/ml) so this drug can also be used as a drug of choice in for P. aeruginosa. Good susceptibility was established to amikacin (60.2%, and 33.6% resistant strains with MIC50 12,5 μg/ml). Moderate susceptibility was established to ciprofloxacin (45.8% susceptible strains and 49.3% resistant strains with MIC50 1,56 μg/ml). Poor susceptibility was established to ofloxacin and fleroxacin with 57.4% resistant strains to ofloxacin and 59% to fleroxacin; moderate susceptibility to ofloxacin was established for 25.6% of strains and to fleroxacin for 30.4%; only 17% of strains were ofloxacin susceptible and 10.6% fleroxacin susceptible, with MIC50 6,3 μg/ml, discrediting both drugs as antipseudomonas drugs., U radu je testirano 312 sojeva Ps. aeruginosa. Od toga 70 % izolata potiče iz urina, a preostalih 30% potiče iz različitog patološkog materijala. Osetljivost Ps. aeruginosa ispitivana je prema: Piperacilinu, Amikacinu Ceftazidimu, Ciprofloksacinu, Ofloksacinu i Fleroksacinu. Za ispitivanje osetljivosti Ps. aeruginosa na rezervne lekove, korišćen je agar-dilucioni metod, pri čemu je osetljivost ove bakterije izražena minimalnom inhibitornom koncentracijom (MIC). Na osnovu našeg rada vodeći među testiranim antibioticima je antipseudomonasni lek Piperacilin sa 93,6% piperacilin osetljivih sojeva i svega 6,4% piperacilin rezistentnih sojeva i MIC50 6,3mg/ml. Visoku osetljivost ispitivani sojevi Ps. aeruginosa pokazali su prema Ceftazidimu sa 82% Ceftazidim osetljivih i svega 10,6% Ceftazidim rezistentnih sojeva i MIC50 3,1mg/ml, te se i on može koristiti kao lek izbora za Ps. aeruginosa. Dobru osetljivost pokazali su ispitivani sojevi prema Amikacinu 60,2% je Amikacin osetljivih sojeva i 33,6% Amikacin rezistentnih sojeva sa MIC50 12,5mg/ml. Umerenu osetljivost pokazali su ispitivani sojevi prema Ciprofloksacinu sa 45,8% osetljivih i 49,3% rezistentnih sojeva i MIC50 1,56mg/ml. Slabu osetljivost pokazali su ispitivani sojevi prema Ofloksacinu i Fleroksacinu, pri čemu je Ofloksacin rezistentnih sojeva 57,4%, odnosno Fleroksacin rezistentnih 59%; umereno Ofloksacin osetljivih 25,6%, odnosno umereno Fleroksacin osetljivih 30,4% i svega Ofloksacin osetljivih 17%, odnosno Fleroksacin osetljivih 10,6% a MIC50 Ofloksacina i Fleroksacina je 6,3mg/ml, što ova dva leka i diskredituje iz grupe antipseudomonasnih lekova.", publisher = "Nestranačko, nevladino i neprofitno udruženje građana Medicina danas - pokret evropskih inicijativa, Novi Sad", journal = "Medicina danas", title = "Pseudomonas aeruginosa and reserve drugs, Pseudomonas aeruginosa i rezervni lekovi", pages = "180-176", number = "1-2", volume = "3", url = "https://hdl.handle.net/21.15107/rcub_intor_186" }
Aleksić-Živić, J., Mraović, M.,& Živić, M.. (2004). Pseudomonas aeruginosa and reserve drugs. in Medicina danas Nestranačko, nevladino i neprofitno udruženje građana Medicina danas - pokret evropskih inicijativa, Novi Sad., 3(1-2), 176-180. https://hdl.handle.net/21.15107/rcub_intor_186
Aleksić-Živić J, Mraović M, Živić M. Pseudomonas aeruginosa and reserve drugs. in Medicina danas. 2004;3(1-2):176-180. https://hdl.handle.net/21.15107/rcub_intor_186 .
Aleksić-Živić, Jasminka, Mraović, Mirjana, Živić, Milan, "Pseudomonas aeruginosa and reserve drugs" in Medicina danas, 3, no. 1-2 (2004):176-180, https://hdl.handle.net/21.15107/rcub_intor_186 .